A Phase 2 interventional study of CP-690,550 and placebo in Rheumatoid Arthritis, sponsored by Pfizer. Completed at 57 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-03-29.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing tofacitinib in Arthritis, Rheumatoid — 9 open to participants now, 9 under way, 1 of them phase 3. tofacitinib · Arthritis, Rheumatoid.
Among the 43 studies testing tofacitinib in Arthritis, Rheumatoid, this one is the 20th largest by enrollment, is one of 2 that started in 2011, is one of 12 in phase 2, and was the 19th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →9 of the 43 studies testing tofacitinib in Arthritis, Rheumatoid are open now, in 6 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Shaikh Zayed Hospital, Lahore · Sites in Pakistan
Ages 50–85
University Hospital, Toulouse · Sites in France
Ages 18–65
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–65
Marie Hudson, MD · Sites in Canada
Ages 18+
By country, each count listing its studies:
tofacitinib: first FDA approval 2012 (XELJANZ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 223 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 170 across the 43 interventional studies. Of the 30 that completed or were terminated, 23 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 43 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
152 studies in Arthritis, Rheumatoid by Pfizer: 2 open now, 2 under way, none of them phase 3. Of 149 finished, 105 (70%) have results posted.
Among the 152 studies in Arthritis, Rheumatoid by Pfizer, this one is the 34th largest by enrollment of the 86 interventional ones that give a count, is one of 9 that started in 2011, is one of 28 in phase 2, and was the 88th registered.
Pfizer’s Arthritis, Rheumatoid studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 43 studies testing tofacitinib in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 152 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A Randomized, Double Blind, Placebo Controlled Phase 2 Study To assess the Immune Response Following Administration of Influenza and Pneumococcal Vaccines to Subjects with Rheumatoid Arthritis receiving CP-690,550 with and Without background Methotrexate
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
CP-690,550 will be administered for 4 weeks, vaccines will be administered at week 4. CP-690,550 will then continue for another 5 weeks at which point the immune response will be evaluated.
Drug: CP-690,550
Placebo will be administered for 4 weeks, vaccines will be administered at week 4. Placebo will then continue for another 5 weeks at which point the immune response will be evaluated.
Drug: placebo
Treatment Group 1: 10 mg BID CP-690,550 (100 subjects). Strata 1: 10 mg BID CP-690,550 on background methotrexate (50 subjects); Strata 2: 10 mg BID CP-690,550 monotherapy (50 subjects).
Placebo CP-690,550 (100 subjects). Strata 1: Placebo CP-690,550 on background methotrexate (50 subjects); Strata 2: Placebo CP-690,550 monotherapy (50 subjects). Influenza and pneumococcal vaccines will be administered to all subjects
Percentage of Participants With Satisfactory Humoral Response to the Pneumococcal Vaccine at Visit 3 (Day 64)
Satisfactory humoral response to the pneumococcal vaccine was defined as greater than or equal to (\>=) 2 fold increase in antibody concentrations from vaccination baseline (Day 29) in at least 6 of 12 pneumococcal antigens (1, 3, 4, 5, 6B, 7F, 9V, 14, 19A, 19F, 23F, 18C). Data was stratified by the background methotrexate use.
Time frame: Day 64 (End of Study [EOS])
Percentage of Participants With Satisfactory Humoral Response to the Seasonal Influenza Vaccine at Visit 3 (Day 64)
Satisfactory humoral response to the influenza vaccine was defined as \>= 4 fold increase in antibody titers from vaccination baseline (Day 29) in at least 2 of 3 influenza antigens (B, H1N1, H3N2). Data was stratified by the background methotrexate use.
Time frame: Day 64 (EOS)
Percentage of Participants Who Responded to Each of the 12 Pneumococcal Antigens
Response to the pneumococcal vaccine (seroconversion) was defined as \>= 2 fold increase in antibody concentrations from vaccination baseline (Day 29) in each of the 12 pneumococcal antigens (1, 3, 4, 5, 6B, 7F, 9V, 14, 19A, 19F, 23F, 18C). Data was stratified by the background methotrexate use.
Time frame: Day 64 (EOS)
Percentage of Participants Who Responded to Each of the 3 Influenza Antigens
Response to the influenza vaccine (seroconversion) was defined as \>= 4 fold increase in antibody titers from vaccination baseline (Day 29) in each of 3 influenza antigens (B, H1N1, H3N2). Data was stratified by the background methotrexate use.
Time frame: Day 64 (EOS)
Percentage of Participants With Protective Antibody Titers to the Seasonal Influenza Vaccine
Seroprotection was defined as achieving protective antibody titers to the influenza vaccine as measured by a hemagglutination inhibition (HAI) assay titer of \>= 1:40 in at least 2 of 3 influenza antigens (B, H1N1, H3N2). Data was stratified by the background methotrexate use.
Time frame: Day 64 (EOS)
Geometric Mean Fold Rise (GMFR) of Anti-Pneumococcal Antibody Levels to Each of the 12 Pneumococcal Antigens Above Vaccination Baseline Values (Day 29)
Geometric mean fold rises (GMFRs) for the 12 pneumococcal antigens (1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) from pre-vaccination (Day 29) to Day 64 (Day 35 post-vaccination) were computed using the logarithmically transformed assay results. Confidence intervals (CIs) for GMFR are back transformations of a CI based on the Student t-distribution for the mean logarithm of the titers. Data was stratified by the background methotrexate use.
Time frame: Day 64 (EOS)
Geometric Mean Fold Rise (GMFR) of Anti-Influenza Antibody Levels to Each of the Influenza Antigens Above Vaccination Baseline Values (Day 29)
GMFRs for the 3 influenza antigens (B, H1N1, H3N2) from pre-vaccination (Day 29) to Day 64 (Day 35 post-vaccination) were computed using the logarithmically transformed assay results. CIs for GMFR are back transformations of a CI based on the Student t-distribution for the mean logarithm of the titers. Data was stratified by the background methotrexate use.
Time frame: Day 64 (EOS)
Geometric Mean Concentrations (GMC) of Anti-Pneumococcal Antibody
Antibody geometric mean concentration (GMC) for 12 pneumococcal antigens (1, 3, 4, 5, 6B, 7F, 9V, 14, 19A, 19F, 23F, 18C) as measured by geometric mean of three independent determinations of the antibody response of that antigen. GMC and corresponding 2-sided 95% confidence intervals (CI) were evaluated.
Time frame: Day 64 (EOS)
Geometric Mean Titer (GMT) of Anti-Influenza Antibody
Antibody geometric mean titer (GMT) for 3 influenza antigens antigens (B, H1N1, H3N2) as measured by geometric mean of three independent determinations of the antibody response of that antigen. GMT and corresponding 2-sided 95% confidence intervals (CI) were evaluated.
Time frame: Day 64 (EOS)
| Milestone | CP-690,550 + Influenza and Pneumococcal Vaccine | Placebo + Influenza and Pneumococcal Vaccine |
|---|---|---|
| Started | 112 | 111 |
| Completed | 105 | 106 |
| Not completed | 7 | 5 |
| Withdrew: Lack of efficacy | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Adverse event | 4 | 3 |
| Withdrew: Other | 1 | 0 |
Satisfactory humoral response to the pneumococcal vaccine was defined as greater than or equal to (\>=) 2 fold increase in antibody concentrations from vaccination baseline (Day 29) in at least 6 of 12 pneumococcal antigens (1, 3, 4, 5, 6B, 7F, 9V, 14, 19A, 19F, 23F, 18C). Data was stratified by the background methotrexate use.
| percentage of participants | CP-690,550 + Influenza and Pneumococcal Vaccine | Placebo + Influenza and Pneumococcal Vaccine |
|---|---|---|
| Regardless MTX use (n=102,98) | 45.1 (35.224 to 55.264) | 68.4 (58.196 to 77.394) |
| With BG MTX use (n=57,55) | 31.6 (19.905 to 45.243) | 61.8 (47.726 to 74.591) |
| Without BG MTX use (n=45,43) | 62.2 (46.541 to 76.232) | 76.7 (61.369 to 88.245) |
Satisfactory humoral response to the influenza vaccine was defined as \>= 4 fold increase in antibody titers from vaccination baseline (Day 29) in at least 2 of 3 influenza antigens (B, H1N1, H3N2). Data was stratified by the background methotrexate use.
| percentage of participants | CP-690,550 + Influenza and Pneumococcal Vaccine | Placebo + Influenza and Pneumococcal Vaccine |
|---|---|---|
| Regardless MTX use (n=102,98) | 56.9 (46.682 to 66.634) | 62.2 (51.885 to 71.844) |
| With BG MTX use (n=57,55) | 50.9 (37.29 to 64.37) | 58.2 (44.106 to 71.345) |
| Without BG MTX use (n=45,43) | 64.4 (48.78 to 78.132) | 67.4 (51.456 to 80.924) |
Response to the pneumococcal vaccine (seroconversion) was defined as \>= 2 fold increase in antibody concentrations from vaccination baseline (Day 29) in each of the 12 pneumococcal antigens (1, 3, 4, 5, 6B, 7F, 9V, 14, 19A, 19F, 23F, 18C). Data was stratified by the background methotrexate use.
| percentage of participants | CP-690,550 + Influenza and Pneumococcal Vaccine | Placebo + Influenza and Pneumococcal Vaccine |
|---|---|---|
| Regardless MTX use, 1 (n=102,98) | 59.8 (49.63 to 69.393) | 69.4 (59.265 to 78.302) |
| Regardless MTX use, 14 (n=102,98) | 52 (41.844 to 61.961) | 61.2 (50.849 to 70.903) |
| Regardless MTX use, 18C (n=102,98) | 59.8 (49.63 to 69.393) | 70.4 (60.338 to 79.205) |
| Regardless MTX use, 19A (n=102,98) | 32.4 (23.424 to 42.337) | 46.9 (36.778 to 57.289) |
| Regardless MTX use, 19F (n=102,98) | 35.3 (26.086 to 45.38) | 56.1 (45.732 to 66.133) |
| Regardless MTX use, 23F (n=102,98) | 40.2 (30.607 to 50.37) | 58.2 (47.766 to 68.054) |
| Regardless MTX use, 3 (n=102,98) | 38.2 (28.787 to 48.386) | 54.1 (43.714 to 64.196) |
| Regardless MTX use, 4 (n=102,98) | 58.8 (48.644 to 68.477) | 65.3 (55.02 to 74.64) |
| Regardless MTX use, 5 (n=102,98) | 28.4 (19.938 to 38.218) | 38.8 (29.097 to 49.151) |
| Regardless MTX use, 6B (n=102,98) | 36.3 (26.982 to 46.386) | 54.1 (43.714 to 64.196) |
| Regardless MTX use, 7F (n=102,98) | 58.8 (48.644 to 68.477) | 65.3 (55.02 to 74.64) |
| Regardless MTX use, 9V (n=102,98) | 45.1 (35.224 to 55.264) | 58.2 (47.766 to 68.054) |
| With BG MTX use, 1 (n=57,55) | 57.9 (44.084 to 70.857) | 61.8 (47.726 to 74.591) |
| With BG MTX use, 14 (n=57,55) | 47.4 (33.985 to 61.035) | 56.4 (42.322 to 69.696) |
| With BG MTX use, 18C (n=57,55) | 49.1 (35.63 to 62.71) | 58.2 (44.106 to 71.345) |
| With BG MTX use, 19A (n=57,55) | 19.3 (10.047 to 31.911) | 40 (27.023 to 54.093) |
| With BG MTX use, 19F (n=57,55) | 28.1 (16.973 to 41.543) | 49.1 (35.354 to 62.929) |
| With BG MTX use, 23F (n=57,55) | 24.6 (14.127 to 37.761) | 49.1 (35.354 to 62.929) |
| With BG MTX use, 3 (n=57,55) | 24.6 (14.127 to 37.761) | 49.1 (35.354 to 62.929) |
| With BG MTX use, 4 (n=57,55) | 52.6 (38.965 to 66.015) | 56.4 (42.322 to 69.696) |
| With BG MTX use, 5 (n=57,55) | 28.1 (16.973 to 41.543) | 29.1 (17.63 to 42.898) |
| With BG MTX use, 6B (n=57,55) | 29.8 (18.429 to 43.403) | 47.3 (33.653 to 61.196) |
| With BG MTX use, 7F (n=57,55) | 49.1 (35.63 to 62.71) | 56.4 (42.322 to 69.696) |
| With BG MTX use, 9V (n=57,55) | 33.3 (21.401 to 47.065) | 49.1 (35.354 to 62.929) |
| Without BG MTX use, 1 (n=45,43) | 62.2 (46.541 to 76.232) | 79.1 (63.958 to 89.956) |
| Without BG MTX use, 14 (n=45,43) | 57.8 (42.15 to 72.343) | 67.4 (51.456 to 80.924) |
| Without BG MTX use, 18C (n=45,43) | 73.3 (58.055 to 85.396) | 86 (72.068 to 94.702) |
| Without BG MTX use, 19A (n=45,43) | 48.9 (33.703 to 64.226) | 55.8 (39.875 to 70.922) |
| Without BG MTX use, 19F (n=45,43) | 44.4 (29.644 to 60.003) | 65.1 (49.073 to 78.992) |
| Without BG MTX use, 23F (n=45,43) | 60 (44.331 to 74.302) | 69.8 (53.875 to 82.818) |
| Without BG MTX use, 3 (n=45,43) | 55.6 (39.997 to 70.356) | 60.5 (44.41 to 75.023) |
| Without BG MTX use, 4 (n=45,43) | 66.7 (51.05 to 79.999) | 76.7 (61.369 to 88.245) |
| Without BG MTX use, 5 (n=45,43) | 28.9 (16.366 to 44.315) | 51.2 (35.465 to 66.695) |
| Without BG MTX use, 6B (n=45,43) | 44.4 (29.644 to 60.003) | 62.8 (46.725 to 77.025) |
| Without BG MTX use, 7F (n=45,43) | 71.1 (55.685 to 83.634) | 76.7 (61.369 to 88.245) |
| Without BG MTX use, 9V (n=45,43) | 60 (44.331 to 74.302) | 69.8 (53.875 to 82.818) |
Response to the influenza vaccine (seroconversion) was defined as \>= 4 fold increase in antibody titers from vaccination baseline (Day 29) in each of 3 influenza antigens (B, H1N1, H3N2). Data was stratified by the background methotrexate use.
| percentage of participants | CP-690,550 + Influenza and Pneumococcal Vaccine | Placebo + Influenza and Pneumococcal Vaccine |
|---|---|---|
| Regardless MTX use, B (n=102,98) | 38.2 (28.787 to 48.386) | 52 (41.712 to 62.243) |
| Regardless MTX use, H1N1 (n=102,98) | 60.8 (50.62 to 70.305) | 63.3 (52.925 to 72.781) |
| Regardless MTX use, H3N2 (n=102,98) | 60.8 (50.62 to 70.305) | 69.4 (59.265 to 78.302) |
| With BG MTX use, B (n=57,55) | 35.1 (22.915 to 48.869) | 41.8 (28.655 to 55.894) |
| With BG MTX use, H1N1 (n=57,55) | 52.6 (38.965 to 66.015) | 58.2 (44.106 to 71.345) |
| With BG MTX use, H3N2 (n=57,55) | 57.9 (44.084 to 70.857) | 65.5 (51.419 to 77.763) |
| Without BG MTX use, B (n=45,43) | 42.2 (27.657 to 57.85) | 65.1 (49.073 to 78.992) |
| Without BG MTX use, H1N1 (n=45,43) | 71.1 (55.685 to 83.634) | 69.8 (53.875 to 82.818) |
| Without BG MTX use, H3N2 (n=45,43) | 64.4 (48.78 to 78.132) | 74.4 (58.828 to 86.481) |
Seroprotection was defined as achieving protective antibody titers to the influenza vaccine as measured by a hemagglutination inhibition (HAI) assay titer of \>= 1:40 in at least 2 of 3 influenza antigens (B, H1N1, H3N2). Data was stratified by the background methotrexate use.
| percentage of participants | CP-690,550 + Influenza and Pneumococcal Vaccine | Placebo + Influenza and Pneumococcal Vaccine |
|---|---|---|
| Regardless MTX use (n=102,98) | 76.5 (67.043 to 84.305) | 91.8 (84.547 to 96.41) |
| With BG MTX use (n=57,55) | 64.9 (51.131 to 77.085) | 92.7 (82.413 to 97.983) |
| Without BG MTX use (n=45,43) | 91.1 (78.779 to 97.525) | 90.7 (77.865 to 97.407) |
Geometric mean fold rises (GMFRs) for the 12 pneumococcal antigens (1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) from pre-vaccination (Day 29) to Day 64 (Day 35 post-vaccination) were computed using the logarithmically transformed assay results. Confidence intervals (CIs) for GMFR are back transformations of a CI based on the Student t-distribution for the mean logarithm of the titers. Data was stratified by the background methotrexate use.
| fold rise | CP-690,550 + Influenza and Pneumococcal Vaccine | Placebo + Influenza and Pneumococcal Vaccine |
|---|---|---|
| Regardless MTX use, 1 (n=89,92) | 4.75 (3.61 to 6.24) | 6.83 (4.94 to 9.46) |
| Regardless MTX use, 14 (n=101,96) | 2.68 (2.19 to 3.28) | 3.90 (3.05 to 4.99) |
| Regardless MTX use, 18C (n=101,98) | 3.10 (2.52 to 3.81) | 4.82 (3.76 to 6.18) |
| Regardless MTX use, 19A (n=102,98) | 1.80 (1.56 to 2.08) | 2.34 (1.99 to 2.75) |
| Regardless MTX use, 19F (n=102,95) | 2.04 (1.71 to 2.42) | 2.89 (2.40 to 3.49) |
| Regardless MTX use, 23F (n=102,98) | 2.00 (1.64 to 2.44) | 2.81 (2.34 to 3.36) |
| Regardless MTX use, 3 (n=101,94) | 2.11 (1.76 to 2.54) | 2.79 (2.31 to 3.38) |
| Regardless MTX use, 4 (n=96,89) | 3.10 (2.49 to 3.86) | 5.13 (3.94 to 6.67) |
| Regardless MTX use, 5 (n=101,98) | 1.72 (1.50 to 1.97) | 2.27 (1.91 to 2.70) |
| Regardless MTX use, 6B (n=102,98) | 1.90 (1.61 to 2.24) | 2.56 (2.12 to 3.10) |
| Regardless MTX use, 7F (n=102,97) | 3.19 (2.59 to 3.93) | 4.06 (3.27 to 5.04) |
| Regardless MTX use, 9V (n=102,98) | 2.27 (1.85 to 2.55) | 3.16 (2.59 to 3.86) |
| With BG MTX use, 1 (n=49,53) | 3.92 (2.77 to 5.54) | 4.51 (3.00 to 6.77) |
| With BG MTX use, 14 (n=56,54) | 2.37 (1.84 to 3.04) | 2.85 (2.19 to 3.72) |
| With BG MTX use, 18C (n=57,55) | 2.64 (2.05 to 3.41) | 3.23 (2.45 to 4.26) |
| With BG MTX use, 19A (n=57,55) | 1.51 (1.30 to 1.74) | 2.08 (1.67 to 2.59) |
| With BG MTX use, 19F (n=57,53) | 1.92 (1.51 to 2.44) | 2.29 (1.88 to 2.79) |
| With BG MTX use, 23F (n=57,55) | 1.66 (1.32 to 2.07) | 2.34 (1.88 to 2.91) |
| With BG MTX use, 3 (n=56,54) | 1.78 (1.39 to 2.27) | 2.43 (1.90 to 3.12) |
| With BG MTX use, 4 (n=53,50) | 2.92 (2.22 to 3.85) | 3.27 (2.51 to 4.25) |
| With BG MTX use, 5 (n=57,55) | 1.62 (1.35 to 1.95) | 1.99 (1.59 to 2.50) |
| With BG MTX use, 6B (n=57,55) | 1.60 (1.37 to 1.88) | 2.24 (1.79 to 2.81) |
| With BG MTX use, 7F (n=57,55) | 2.38 (1.89 to 2.98) | 3.46 (2.57 to 4.64) |
| With BG MTX use, 9V (n=57,55) | 1.87 (1.53 to 2.29) | 2.72 (2.08 to 3.54) |
| Without BG MTX use, 1 (n=40,39) | 6.01 (3.85 to 9.37) | 12.04 (7.34 to 19.74) |
| Without BG MTX use, 14 (n=45,42) | 3.14 (2.25 to 4.37) | 5.85 (3.81 to 8.99) |
| Without BG MTX use, 18C (n=44,43) | 3.80 (2.70 to 5.35) | 8.05 (5.37 to 12.08) |
| Without BG MTX use, 19A (n=45,43) | 2.27 (1.75 to 2.94) | 2.72 (2.13 to 3.47) |
| Without BG MTX use, 19F (n=45,42) | 2.19 (1.68 to 2.85) | 3.88 (2.78 to 5.43) |
| Without BG MTX use, 23F (n=45,43) | 2.54 (1.81 to 3.58) | 3.55 (2.63 to 4.78) |
| Without BG MTX use, 3 (n=45,40) | 2.61 (1.98 to 3.44) | 3.37 (2.49 to 4.55) |
| Without BG MTX use, 4 (n=43,39) | 3.32 (2.31 to 4.79) | 9.15 (5.85 to 14.29) |
| Without BG MTX use, 5 (n=44,43) | 1.86 (1.50 to 2.29) | 2.68 (2.04 to 3.52) |
| Without BG MTX use, 6B (n=45,43) | 2.36 (1.73 to 3.21) | 3.04 (2.19 to 4.21) |
| Without BG MTX use, 7F (n=45,42) | 4.62 (3.23 to 6.60) | 5.02 (3.65 to 6.90) |
| Without BG MTX use, 9V (n=45,43) | 2.63 (2.03 to 3.41) | 3.83 (2.82 to 5.19) |
GMFRs for the 3 influenza antigens (B, H1N1, H3N2) from pre-vaccination (Day 29) to Day 64 (Day 35 post-vaccination) were computed using the logarithmically transformed assay results. CIs for GMFR are back transformations of a CI based on the Student t-distribution for the mean logarithm of the titers. Data was stratified by the background methotrexate use.
| fold rise | CP-690,550 + Influenza and Pneumococcal Vaccine | Placebo + Influenza and Pneumococcal Vaccine |
|---|---|---|
| Regardless MTX use, B (n=102,98) | 2.95 (2.32 to 3.75) | 3.90 (3.06 to 4.97) |
| Regardless MTX use, H1N1 (n=102,98) | 6.04 (4.59 to 7.95) | 9.50 (6.76 to 13.35) |
| Regardless MTX use, H3N2 (n=102,98) | 7.11 (5.18 to 9.75) | 9.06 (6.61 to 12.44) |
| With BG MTX use, B (n=57,55) | 2.84 (2.02 to 3.98) | 3.11 (2.27 to 4.26) |
| With BG MTX use, H1N1 (n=57,55) | 4.90 (3.43 to 7.00) | 7.54 (4.80 to 11.85) |
| With BG MTX use, H3N2 (n=57,55) | 5.69 (3.88 to 8.34) | 6.04 (4.18 to 8.73) |
| Without BG MTX use, B (n=45,43) | 3.11 (2.20 to 4.40) | 5.20 (3.57 to 7.57) |
| Without BG MTX use, H1N1 (n=45,43) | 7.88 (5.13 to 12.10) | 12.76 (7.56 to 21.53) |
| Without BG MTX use, H3N2 (n=45,43) | 9.43 (5.52 to 16.09) | 15.25 (9.06 to 25.66) |
Antibody geometric mean concentration (GMC) for 12 pneumococcal antigens (1, 3, 4, 5, 6B, 7F, 9V, 14, 19A, 19F, 23F, 18C) as measured by geometric mean of three independent determinations of the antibody response of that antigen. GMC and corresponding 2-sided 95% confidence intervals (CI) were evaluated.
| microgram/milliliter (mcg/mL) | CP-690,550 + Influenza and Pneumococcal Vaccine | Placebo + Influenza and Pneumococcal Vaccine |
|---|---|---|
| 1 | 1.81 (1.32 to 2.48) | 3.27 (2.34 to 4.58) |
| 14 | 5.24 (3.85 to 7.12) | 6.40 (4.63 to 8.84) |
| 18C | 2.53 (1.95 to 3.29) | 4.60 (3.48 to 6.09) |
| 19A | 5.21 (4.15 to 6.54) | 8.57 (6.86 to 10.70) |
| 19F | 2.59 (1.93 to 3.47) | 3.09 (2.28 to 4.19) |
| 23F | 2.41 (1.86 to 3.11) | 3.55 (2.78 to 4.55) |
| 3 | 0.66 (0.52 to 0.86) | 1.11 (0.86 to 1.43) |
| 4 | 0.72 (0.54 to 0.97) | 1.07 (0.77 to 1.48) |
| 5 | 4.05 (3.23 to 5.09) | 5.79 (4.60 to 7.30) |
| 6B | 2.99 (2.34 to 3.83) | 4.75 (3.71 to 6.07) |
| 7F | 3.28 (2.42 to 4.45) | 4.37 (3.36 to 5.67) |
| 9V | 2.61 (2.11 to 3.23) | 4.06 (3.29 to 5.01) |
Antibody geometric mean titer (GMT) for 3 influenza antigens antigens (B, H1N1, H3N2) as measured by geometric mean of three independent determinations of the antibody response of that antigen. GMT and corresponding 2-sided 95% confidence intervals (CI) were evaluated.
| titer | CP-690,550 + Influenza and Pneumococcal Vaccine | Placebo + Influenza and Pneumococcal Vaccine |
|---|---|---|
| B | 33.39 (25.61 to 43.54) | 50.74 (39.82 to 64.64) |
| H1N1 | 86.40 (64.35 to 116.0) | 221.5 (161.4 to 304.0) |
| H3N2 | 132.3 (97.65 to 179.1) | 244.0 (184.6 to 322.5) |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CP-690,550 + Influenza and Pneumococcal Vaccine | — | 4/112 (3.6%) | 17/112 (15.2%) |
| Placebo + Influenza and Pneumococcal Vaccine | — | 1/111 (0.9%) | 17/111 (15.3%) |
| Event | CP-690,550 + Influenza and Pneumococcal Vaccine | Placebo + Influenza and Pneumococcal Vaccine |
|---|---|---|
| CellulitisInfections and infestations | 0/112 | 1/111 |
| Atrial fibrillationCardiac disorders | 1/112 | 0/111 |
| Chest painGeneral disorders | 1/112 | 0/111 |
| PneumoniaInfections and infestations | 1/112 | 0/111 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 1/112 | 0/111 |
| Event | CP-690,550 + Influenza and Pneumococcal Vaccine | Placebo + Influenza and Pneumococcal Vaccine |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 6/112 | 8/111 |
| HeadacheNervous system disorders | 5/112 | 1/111 |
| DiarrhoeaGastrointestinal disorders | 1/112 | 4/111 |
| Urinary tract infectionInfections and infestations | 3/112 | 4/111 |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 0/112 | 3/111 |
| DizzinessNervous system disorders | 3/112 | 0/111 |
| Sinus congestionRespiratory, thoracic and mediastinal disorders | 3/112 | 0/111 |
| Age Continuous(years) | CP-690,550 + Influenza and Pneumococcal Vaccine | Placebo + Influenza and Pneumococcal Vaccine | Total |
|---|---|---|---|
| Mean | 52.7 ± 10.4 | 52.2 ± 11.1 | 52.4 ± 10.8 |
| Sex: Female, Male(Participants) | CP-690,550 + Influenza and Pneumococcal Vaccine | Placebo + Influenza and Pneumococcal Vaccine | Total |
|---|---|---|---|
| Female | 81 | 90 | 171 |
| Male | 31 | 21 | 52 |
| Number of Participants With Background (BG) Methotrexate (MTX) use(participants) | CP-690,550 + Influenza and Pneumococcal Vaccine | Placebo + Influenza and Pneumococcal Vaccine | Total |
|---|---|---|---|
| With Background MTX use | 62 | 62 | 124 |
| Without Background MTX use | 50 | 49 | 99 |
The record gives a start of Sep 2011, a primary completion of Feb 2012 and a completion of Feb 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2013, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tofacitinib